- NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER
-
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, ester or stereoisomer thereof, wherein R1 to R3 and X have the significances given herein. The present invention is also directed to proc
- -
-
-
- NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER
-
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, ester or stereoisomer thereof, wherein R1 to R3 and X have the significances given herein. The present invention is also directed to proc
- -
-
-
- ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF
-
The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.
- -
-
Page/Page column 30
(2008/12/06)
-
- Bicyclic heterocycles as cannabinoid receptor modulators
-
The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, n, and Z are described herein.
- -
-
Page/Page column 9
(2008/06/13)
-
- Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors
-
Tetrahydroquinoline-based small molecule inhibitors of farnesyltransferase (FT) have been identified. Lead compounds were shown to have nanomolar to sub-nanomolar activity in biochemical assays with excellent potency in a Ras-mutated cellular reversion as
- Lombardo, Louis J.,Camuso, Amy,Clark, John,Fager, Krista,Gullo-Brown, Johnni,Hunt, John T.,Inigo, Ivan,Kan, David,Koplowitz, Barry,Lee, Francis,McGlinchey, Kelly,Qian, Ligang,Ricca, Carolyn,Rovnyak, George,Traeger, Sarah,Tokarski, John,Williams, David K.,Wu, Laurence I.,Zhao, Yufen,Manne, Veeraswamy,Bhide, Rajeev S.
-
p. 1895 - 1899
(2007/10/03)
-
- Inhibitors of farnesyl protein transferase
-
Disclosed are quinoline and benzazepine derivatives that inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogenic protein Ras. Thus, the compounds are useful as anti-cancer agents. The compounds are also useful in the treatment of diseases other than cancer.
- -
-
-
